Quick answer
Low-risk prostate cancer has ISUP grade group 1 on biopsy (Gleason 6), a PSA below 10 ng/mL and a tumor confined to the prostate on the rectal exam.1 The European guideline recommends active surveillance for men with a life expectancy above 10 years and considers surgery and radiotherapy in this group likely overtreatment.2 The US NCCN guideline accepts treating some low-risk cases through shared decision-making.3 I assess each case individually.
What low risk means
The European guideline groups prostate cancer by risk using the biopsy ISUP grade group, the PSA and the rectal exam:1
| Group | How it is defined |
|---|---|
| Low risk | ISUP 1, PSA below 10 ng/mL and tumor confined to the prostate on the rectal exam (cT1 or cT2) |
| Intermediate risk | ISUP 2 or 3, or PSA between 10 and 20 ng/mL, with tumor confined to the prostate on the rectal exam |
| High risk | ISUP 4 or 5, or PSA above 20 ng/mL |
A single item outside the top row moves the case out of low risk. A man with Gleason 6 and a PSA of 12 ng/mL, for example, is already intermediate risk. The risk group calculator does this with your own numbers.
The US NCCN guideline keeps a very-low-risk group inside low risk. To fit it, the case needs all of the following:3
- A tumor that cannot be felt on the rectal exam (cT1c)
- ISUP 1 and a PSA below 10 ng/mL
- Fewer than 3 biopsy cores with cancer
- No more than half of any core involved by tumor
- PSA density below 0.15 ng/mL/cc
With MRI-targeted biopsy, fewer men fit this group, because the needle takes several cores from the same lesion. The NCCN counts a targeted lesion that shows cancer in more than one core as a single positive core.3 The page on PSA density explains this calculation.
What Gleason 6 means
Gleason 6 corresponds to ISUP grade group 1, the lowest on the 1-to-5 scale.1 Under the microscope, the tumor glands still resemble normal prostate glands: small, round and separate from one another. The page on Gleason and ISUP explains the whole scale.
The European guideline summarizes what studies of removed prostates show. When the specimen had only ISUP 1, spread beyond the capsule was found in 0.3% of cases and PSA recurrence in 3.5%, with no seminal vesicle invasion and no lymph node metastases.1 For this reason, the guideline considers low-risk cancer insignificant in almost all men.1
Two points call for care:
- The biopsy may have missed the worst part. The guideline highlights a high PSA density, a large amount of tumor in the cores and a visible lesion on MRI with only ISUP 1 on biopsy.1 In a US series from 2004 to 2010, 36.3% of tumors graded Gleason 6 or lower on biopsy had a higher grade in the removed prostate.6
- The grade can rise over time. ISUP 1 progresses to higher grades at about 1% per year.1
This is why low-risk cancer calls for follow-up with scheduled tests.
What the guidelines recommend
The two most widely used guidelines agree on the essentials and differ on a few points:
| Situation | European guideline (EAU) | US guideline (NCCN) |
|---|---|---|
| Life expectancy above 10 years | Active surveillance (strong recommendation) | Active surveillance for most men |
| Life expectancy below 10 years | Watchful waiting (strong recommendation) | Observation, in very low risk |
| Surgery or radiotherapy | Highly likely to be overtreatment; not to be used outside trials | Removed for very low risk; in low risk, may be preferred in some cases, through shared decision-making |
The European guideline bases this on life expectancy, judged by age and other illnesses.2 The US guideline removed surgery and radiotherapy from the very-low-risk options in 2024, after the 15-year results of the ProtecT trial.3
In low risk, the NCCN lists factors that raise the chance of early reclassification: high PSA density, 3 or more cores with cancer, high risk on a tumor genomic test and a BRCA2 mutation. In these cases, up-front surgery or radiotherapy may be preferred, through shared decision-making with the patient.3 In the European guideline, a BRCA2 mutation does not exclude surveillance but calls for careful monitoring.2
Focal therapies, such as HIFU and cryotherapy, are also reserved for trials in low risk.2 Focal therapy has its own page.
How active surveillance works
Active surveillance follows the tumor closely and treats it with curative intent if it changes. The most common entry criteria are ISUP 1, a non-palpable or small tumor on the rectal exam (cT1c or cT2a), a PSA below 10 ng/mL and a PSA density below 0.15 ng/mL/cc. That last threshold is still debated.2 A cribriform or intraductal pattern on the report excludes surveillance.2
Follow-up recommended by the European guideline:2
- PSA: at least every six months.
- Rectal exam: at least once a year.
- MRI: before the confirmatory biopsy, if it was not done before the first biopsy.
- Confirmatory biopsy: 6 to 12 months later, for men who did not have an MRI before the biopsy. Men who had an MRI and a targeted biopsy at the start may skip it.
- Repeat biopsies: with or without MRI, every 2 to 3 years, as long as life expectancy is above 10 years. A common schedule is at 1, 4 and 7 years.
A rise in PSA alone does not change management: it leads to a new MRI and a new biopsy, especially if the PSA doubles in less than 3 years. A worse MRI also needs a biopsy before any decision.2
In the studies summarized by the guideline, cancer-specific survival at 10 years was 98.1% to 100%. More than a third of men are reclassified along the way, and most of them go on to treatment.2
When treatment comes in
The European guideline lists the reasons to stop surveillance:2
- Reclassification on biopsy: a tumor of ISUP 3 or higher, or a cribriform or intraductal pattern. Moving to ISUP 2 does not always end surveillance, especially when the finding comes from a targeted biopsy.
- The patient's wishes: anxiety about surveillance affects about 10% of men and is an accepted reason to treat. Psychological support is an alternative for men who could continue surveillance.
- Health and age: if life expectancy falls below 10 years, follow-up moves to watchful waiting.
The decision to treat is based on the biopsy, not on MRI, PSA or rectal exam alone.2 When treatment comes in, the options are those of the new group, as in intermediate risk and high risk.
What the studies show
Two randomized trials help explain why low-risk cancer is usually monitored:
- ProtecT (United Kingdom): 1,643 men randomized to monitoring, surgery or radiotherapy and followed for 15 years. Death from prostate cancer was 3.1%, 2.2% and 2.9%, with no difference between groups. Metastases were more common with monitoring (9.4%) than with surgery (4.7%) or radiotherapy (5.0%). In the monitoring group, 24.4% were alive without any treatment at the end of the study.4
- PIVOT (United States): 731 men randomized to prostatectomy or observation and followed for up to 19.5 years. Surgery did not significantly reduce mortality. In men with low-risk disease, the difference in overall mortality was 0.7 percentage points, without statistical significance. Urine leakage and erection problems were more common with surgery through 10 years.5
ProtecT has limits for today's low-risk patients. More than a third of the men had intermediate- or high-risk disease, and monitoring relied on PSA alone, without the repeat biopsies of current active surveillance.2,4 The European guideline attributes the higher number of metastases, compared with surveillance series, to this difference.2
If you choose treatment
When treatment is chosen, either because of reclassification or through shared decision-making, the curative options are surgery and radiotherapy. In ProtecT, surgery had a greater effect on erections and continence, and radiotherapy on bowel function.3
I have performed robotic radical prostatectomy since 2020, always with the robot, and I preserve the erection nerves whenever possible. In my practice, the hospital stay is 1 to 2 days (discharge usually happens within 24 hours, still with the catheter), and the catheter stays for 7 to 10 days. Work and driving resume at 2 weeks, and sex and heavy activity at 1 month.
Radiotherapy is the other option, and the page on surgery or radiotherapy compares how each affects urine, erections and the bowel.
How I approach it
In low-risk cancer, I assess each case individually. At the consultation, I review the biopsy report, PSA, PSA density, rectal exam and MRI, confirm that the case really is low risk and explain what each path offers and requires.
If you have just received the report, the page just diagnosed shows the first steps. If you already have a diagnosis and want another assessment, a second opinion can be done entirely online, in English, with your test results sent in advance. I start from the tests you already have, and a review of the slides by a uropathologist is requested only in specific cases.
I have a PhD from the University of São Paulo Medical School, with award-winning research on artificial intelligence in prostate cancer diagnosis, and I have performed more than 1,500 robotic and laparoscopic operations, more than 500 of them robotic.
Send your case
If you have been diagnosed with low-risk cancer and would like my opinion on your case before a consultation, fill in the form below. It goes to my office, and you will get a reply within 24 hours by email or WhatsApp. The form does not replace a consultation: it helps plan the next step.
Frequently asked questions
What is low-risk prostate cancer?+
In the European guideline, it is cancer with ISUP grade group 1 on biopsy (Gleason 6), a PSA below 10 ng/mL and a tumor confined to the prostate on the rectal exam.1 The US NCCN guideline keeps a very-low-risk group inside it, with a non-palpable tumor, fewer than 3 positive cores, no more than half of any core involved and a PSA density below 0.15.3
Is Gleason 6 serious?+
Gleason 6 corresponds to ISUP 1, the lowest grade in use.1 In prostates removed with pure ISUP 1, spread beyond the capsule was found in 0.3% of cases, and there were no lymph node metastases.1 The concern is sampling, because the biopsy may have missed a higher-grade area.1,6
Does low-risk prostate cancer need surgery?+
In the European guideline, the recommended approach is active surveillance for men with a life expectancy above 10 years and watchful waiting for those below 10 years. In this group, surgery and radiotherapy are highly likely to be overtreatment.2 The NCCN accepts surgery or radiotherapy in some low-risk cases, through shared decision-making with the patient.3 I assess each case individually.
How is active surveillance followed up?+
The European guideline recommends a PSA at least every six months, a rectal exam and repeat biopsies, with or without MRI, every 2 to 3 years, as long as life expectancy is above 10 years. If the PSA rises quickly, MRI and biopsy are repeated.2
When does active surveillance turn into treatment?+
The main reason is a biopsy showing ISUP 3 or higher, or a cribriform or intraductal pattern. A change in PSA, rectal exam or MRI alone leads to further testing, and the decision is based on the biopsy.2 Anxiety about surveillance, which affects about 10% of men, is also an accepted reason to treat.2
Can the Gleason 6 on biopsy change after surgery?+
It can. In a study of 7,643 prostatectomies, 36.3% of tumors graded Gleason 6 or lower on biopsy had a higher grade in the removed prostate.6 This is why the European guideline asks for attention to PSA density, the amount of tumor on biopsy and any lesion seen on MRI.1
Who assesses low-risk prostate cancer in São Paulo?+
I do. I am a urologist and robotic surgeon in São Paulo, Brazil, CRM-SP 157.598 and RQE 70.275, with a PhD from the University of São Paulo Medical School, award-winning research on artificial intelligence in prostate cancer diagnosis and more than 1,500 robotic and laparoscopic operations, more than 500 of them robotic. In low-risk disease, I assess each case individually. A second opinion can be done entirely online, in English, with your test results sent in advance.
References
- EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer: classification and staging systems. European Association of Urology; 2026. EAU
- EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer: treatment. European Association of Urology; 2026. EAU
- Schaeffer EM, Srinivas S, Adra N, et al. NCCN Guidelines Insights: Prostate Cancer, Version 3.2024. J Natl Compr Canc Netw. 2024;22(3):140-150. PubMed
- Hamdy FC, Donovan JL, Lane JA, et al. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med. 2023;388(17):1547-1558. PubMed
- Wilt TJ, Jones KM, Barry MJ, et al. Follow-up of Prostatectomy versus Observation for Early Prostate Cancer. N Engl J Med. 2017;377(2):132-142. PubMed
- Epstein JI, Feng Z, Trock BJ, Pierorazio PM. Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. Eur Urol. 2012;61(5):1019-1024. PubMed
Would you like to talk about your case?
In the consultation, I go over your tests and your priorities.
Book a consultation5.0186 Google reviews
